You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
榮昌生物(09995.HK)2024年度營收17.1億元 年度虧損減少至14.68億元
格隆匯 03-27 20:26

格隆匯3月27日丨榮昌生物(09995.HK)公佈年度業績,截至2024年12月31日止年度,公司收益爲人民幣17.102億元,毛利爲人民幣13.674億元。公司銀行結餘及現金爲人民幣7.631億元。2024年度產生開支總額(包括銷售及分銷開支、行政開支及研發開支)爲人民幣28.208億元,其中人民幣15.398億元爲研發開支。稅前虧損減少人民幣4290萬元或2.8%至2024年度人民幣14.684億元。年度虧損減少人民幣4290萬元或2.8%至2024年度人民幣14.684億元。經調整虧損淨額減少人民幣2600萬元或1.8%至2024年度人民幣13.996億元。

公司截至2024年12月31日止年度的產品銷售收益約爲人民幣16.991億元,較去年同期的人民幣10.492億元增長61.9%,主要得益於自身免疫類商業化產品泰它西普(RC18,商品名:泰愛®)及抗腫瘤類商業化產品維迪西妥單抗(RC48,商品名:愛地希?)的強勁銷售增長帶動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account